Kornimate/medical-research-clean huggingface dataset:
using massage of maxillofacial and oral cavity to prevent radioactive oral mucositis

Conditions: Nasopharyngeal Carcinoma

Summary: a total of 160 cases of nasopharyngeal carcinoma patients who met the inclusion criteria were randomly assigned to two groups. the experimental group was given massage of maxillofacial and oral cavity plus routine oral care and functional exercise. the control group was given routine oral care and functional exercise. analyze the difference of incidence of severe acute radioactive oral mucositis in these two groups.

160 nasopharyngeal carcinoma patients were enrolled and randomly assigned to two groups in a 1:1 ratio. the experimental group was given massage of maxillofacial and oral cavity plus routine oral care and functional exercise, the control group was only given routine oral care and functional exercise. assess the condition of oral mucosa, according to the grading standard of rtog acute radiation injury, everyday during radiotherapy. after radiotherapy, follow up the condition of oral mucosa one time per month for a total three times. then analyze the incidence difference between two groups. massage method：the duration of the massage lasts from the first day of radiotherapy to three months after the end of radiotherapy，5 times a day（after getting up, before breakfast, lunch, dinner and going to bed). massage of maxillofacial includes the left and right cheeks, the upper jaw, the lower jaw, and around the mouth. oral massage includes the tongue, hard palate, the gums, and the bucca. each part lasts 1-2min，repeating 3 cycles each time. patients who could finished at least 75% are included in the statistical analysis.

Eligibility criteria:
inclusion criteria: 1. patients diagnosed by pathology with nasopharyngeal carcinoma; 2. ecog ps: 0-2; 3. gender is not limited, age between 18 years old and 70 years old. 4. clear consciousness, no mental illness or cognition impairment; 5. the expected survival time is more than 12 months; exclusion criteria: 1. patients with other severe diseases affecting the quality of life or the treatment process; 2. unwilling to actively cooperate with investigators; 3. patients with previous oral diseases; 4. patients who have received head and neck surgery and radiotherapy; 5. a history of psychotropic substance abuse or a mental disorder; 6. participated in clinical trials of other anti-tumor drugs within 4 weeks before enrollment; 7. women who are pregnant or in lactation; 8. other situations that may affect the results of the clinical study.

Keywords: massage maxillofacial and oral cavity radioactive oral mucositis nasopharyngeal carcinoma
study of iguratimod plus methotrexate compared to leflunomid plus methotrexate in patients with rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: this study is intended to evaluate the efficacy and safety of iguratimod plus methotrexate compared to leflunomid plus methotrexate in patients with active rheumatoid arthritis (ra).


Eligibility criteria:
inclusion criteria: * subjects with a diagnosis of ra according to the diagnostic criteria of the american college of rheumatology (acr) (revised in 1987) * rheumatoid arthritis for more than 3 months from the time of the initial diagnosis * functional class ii-iii * subjects have active ra at the time of screening * subjects with inadequate response to biologics should have a washout period before the initiation of study. for etanercept, washout period should be 2-week, and 8-week for infliximab and adalimumab. * for firstly diagnostic ra patients, the disease activity should be moderate to severe, with das28\>3.2 * must have at least 4 tender joints (66 join count) and 8 swollen joints( 68 join count) at screening and baseline * has a c-reactive protein ≥ 10 mg/l(or 1.0 mg/dl) or erythrocyte sedimentation rate (esr) ≥ 28 mm/hr * must have a negative pregnancy test and use adequate method of contraception throughout the trial * written informed consent exclusion criteria: * preceding treatment with dmards, immunosuppressants (cyclophosphamide, cyclosporine, azathioprine, etc.), or tripterygium within 4 weeks prior to study entry * subjects have been treated with iguratimod or leflunomide combined with mtx before screening. * subjects combined with other autoimmune disease, such as systemic lupus erythematosus (sle), mixed connective tissue disease (mctd), scleriasis and polymyositis, except for sjögren syndrome. * chest x-ray abnormalities, such as tuberculosis, interstitial pulmonary fibrosis, etc. * alt \>1.5×uln, ast \>1.5×uln, cr \>135umol/l, total bilirubin\>1.5×uln * wbc\<4×109/l，hgb\<85g/l，plt\<100×109/l * subjects with serious cardiovascular, renal, hematologic, endocrine diseases or malignant * women of pregnant or breastfeeding, and male or female with recent plan to conception * subjects with immunodeficiency, uncontrolled infection and active gastrointestinal disease * allergic to any of the study drugs * history of alcoholism * subjects with mental illness * subjects receiving live vaccines recently * subjects participating in other clinical study within 3 months prior to study entry
comparison of two stretching techniques in patients suffering from subacromial syndrome

Conditions: Subacromial Impingement Syndrome

Summary: the shoulder stability has always been related to the rotator cuff complex, although more and more is contemplated the teres major muscle and its affectation in the shape of the trigger points within this pathology. as non-invasive measures for the deactivation of these myofascial points, travell and simons recommended the pressure maintained along with muscular stretch. stretching are usually a technique widely used in our practice as physiotherapists and it is necessary to study its effects in the clinic. as an objective we plan to compare the effect of passive stretching in short lever according to the orthopaedic manual therapy concept if it produces better result in the pain, the rank of movement and in the function, with the effect of stretching by means of a long lever in affected patients of subacromial syndrome. this is a randomized controlled study with blind evaluator approved by the ethical committee of the institut d'investigació en atenció primaria jordi gol. after checking the inclusion and exclusion criteria, you will be asked, voluntarily, that the patient sign informed consent. the variables will then be valued independent and dependent on the study. it will randomly be assigned to one of the three groups in the study. the 3 groups receive the protocolized treatment for the service they consist of in superficial thermotherapy, an educational talk and kinesitherapy. the intervention groups will receive alternate days, with a total of six sessions, the stretch corresponding to the group to which they have been assigned. in the case of the long lever group, the intervention consists in a rotary stretch through the humerus as a mobile point. and in the case of the short lever group a stretch of translocation through the scapula as a mobile point. the main variables used will be: age, side effects, habits involving the shoulder, pain intensity, pain threshold at pressure and function, among others. the dependent variables will be measured: pain intensity by means of analogue scale visual, the function through the constant-murley test, the movement range with goniometer and the pressure threshold pain with a pressure gauge brand stech.


Eligibility criteria:
inclusion criteria: * more than 18 years. * present clinical diagnosis of subacromial impingement syndrome * threshold of pain in the teres major muscle pressure less than 2 kg / cm2. * signature of informed consent. exclusion criteria: * pre-shoulder surgery (\<1 year). * inability to keep supine position. * contraindications for stretching: (collagen / tissue diseases connective: ehlers-danlos, morquio, grisel), scars in the healing process or pathological in the area like keloids, acute inflammatory process on the shoulder (\<7 days), severe limitation of the range of movement towards flexion (\<90º passive). * infiltrations (the last 3 months) or during treatment. * be pending litigation or legal claim. * cognitive problems or idiomatic barrier.

Keywords: stretching,teres major, subacromial syndrome, manual therapy
study of human epidermal growth receptor (her2) status evaluation in breast cancer pathology samples

Conditions: Breast Cancer

Summary: a multi-center non-interventional, in-vitro trial for evaluation of concordance of the results for human epidermal growth factor receptor 2 (her2) expression by the immunohistochemical (ihc) method in pathological samples collected from participants with breast cancer.

for accurate selection of participants who will be treated with anti-her2, primary crucial thing to do is the right identification of her2 in breast tumor cells. the advantages and disadvantages of ihc and in-situ hybridization (ish) for the detection of her2 status is still disputable. it is generally agreed on that her2 study should be applied on all invasive breast cancer participants. it can be used together with ihc which measures her2 protein expression or ish which assesses her2 gene amplification. with regard to ihc, the inconsistency of sensitivity and specificity of marketed antibodies, differences in interpretation and technical artifacts cause problems in diagnosis on occasion. there is not enough study on reasons which cause the consistence and discrepancies between laboratories in her2 detection with ihc method.

Eligibility criteria:
inclusion criteria: samples that fulfill all of the criteria will be evaluated for the study. * samples of women aged greater than or equal to (\>/=) 18 and less than (\<) 75 years * tumor samples already diagnosed based on the ihc score of 0 to +3 * samples of primary lesions excluding lymph nodes * 10 percent (%) neutral buffered formalin-fixed and paraffin embedded tissue samples exclusion criteria: samples that fulfill any of the criteria below will not be included in the study. * non-invasive ductal carcinoma (nos) samples * tru-cut biopsies * non-breast cancer pathological samples
studies investigating co-morbidities aggravating heart failure

Conditions: Heart Failure; Type 2 Diabetes Mellitus

Summary: sica-hf is a prospective, multicentre, multinational, longitudinal, pathophysiological evaluation study, which is being conducted in 11 centres across six countries. sica-hf receives funding from the european commission's seventh framework programme (fp7/2007-2013) under grant agreement no. 241558 (sica-hf) and from the russian ministry of science and education within the file transfer protocol "r\&d in priority fields of the s\&t complex of russia 2007-2012" under state contract number 02.527.11.0007. the aim of sica-hf is to provide detailed characteristics of co-morbidities of heart failure at baseline and over time, particularly with regards to obesity, cachexia, and type 2 diabetes.

sica-hf, consisting of outstanding european heart failure clinicians and basic researchers, has accomplished to provide a common platform for the two different research teams. all partners of sica-hf recruited more than 1462 patients with chronic heart failure, 199 patients with type 2 diabetes without heart failure, and 173 healthy control subjects. thus, during the last year, a cumulative 91.4% of the target value was achieved for patients with chronic heart failure, 66.3% of the target value for diabetic controls, and 115.3% and thus over-achieving for healthy subjects. the data of all participating centers were collected and entered into the central database. as of this writing, 1469 of all chronic heart failure patients' visits, 255 of diabetic controls' visits, and 167 healthy controls' visits have been entered into the online database. in total, 171 patients have been reported to be deceased; the total number of hospitalizations is 2232.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of heart failure; * objective evidence of cardiac dysfunctions as evidenced by at least one of the following: * left ventricular ejection fraction ≤ 40%; * left atrial dimension \>4.0 cm (or \>2.5 cm/m in height) * nt-probnp \>400 pg/ml \[\>47.3 pmol/l\] (or bnp \>150 pg/ml) * current treatment with loop diuretics; * age \>18 years; * willingness to provide informed consent exclusion criteria: * congenital heart disease; * any life-threatening disease other than heart failure; * active malignancy of any type, or history of a malignancy within previous 5 years; * previous heart transplantation; * intra-venous therapy for heart failure given within the previous 72 hours; * severe neuro-muscular disease; * history of unstable angina, myocardial infarction or stroke within 3 months prior to the study; * pregnancy; * treatment with immunosuppressive therapy, e.g. steroids for rheumatoid arthritis or obstructive lung disease; * significant renal dysfunction, defined as serum creatinine \>250 μmol/l \[\>2.8 mg/dl\]; * severe liver disease, defined as any liver function tests \>3 times the upper limit of normal; * unable to understand and comply with protocol or to give informed consent.
protective genetic factors against neurological diseases

Conditions: Neurological Disorder; Healthy Control

Summary: nih precision medicine initiative, started in may 2018, will enroll one million people through an online portal. it hopes to identify genetic variants affecting a variety of human phenotypic outcomes. a giant set of data like this may enable an association of genetic variants with a certain phenotype. however, the association is often compromised due to the collection of phenotypic data that is not well controlled or standardized creating "noisy" data. these phenotypic "noises" can be largely eliminated in clinical studies with stringent criteria and standardization of outcome measurements. in this study, by looking mainly at genetic information and nerve conduction speed, we hope to eliminate the extra "noises" in the data set. eliminating the extra "noises" should allow us to be able to determine if there are genetic differences between neurological disorders and healthy controls, and if these genetic differences can be attributed to the speed of the nerve conduction.


Eligibility criteria:
inclusion criteria: 1. diagnosis of a neurological disorder - inherited peripheral neuropathy, charcot marie tooth, multiple sclerosis, or parkinson's disease 2. healthy volunteers with no history of medical conditions known to afflict the nervous system will be recruited as normal controls. 3. age 18-100 (inclusive) 4. able to undergo mri 5. medically stable exclusion criteria: 1. any subject unwilling to undergo genetic testing (dna sampling) 2. any subjects with history of peripheral nerve diseases or conditions known to affect the cns, such as diabetes, stroke, thyroid disease, chemotherapy, renal failure, etc. note: this study holds no additional risk for pregnant women and they will not be excluded.
a study to evaluate the efficacy and safety of ak120 in subjects with moderate to severe atopic dermatitis

Conditions: Atopic Dermatitis

Summary: this is a multicenter, open label phase ii clinical study to evaluate the efficacy and safety of ak120 in the treatment of subjects with moderate to severe atopic dermatitis.

this is a multicenter, open label phase ii clinical study to evaluate the efficacy and safety of ak120 in the treatment of subjects with moderate to severe atopic dermatitis. the total duration of the study (including screening period, treatment period and follow-up period) planned for each subject is approximately 25 weeks.

Eligibility criteria:
inclusion criteria: 1. male or female subjects aged ≥18≤75 years old. 2. atopic dermatitis (ad) diagnosed at least half a year before screening. 3. subject with easi score ≥16, iga ≥ 3, bsa ≥ 10% at screening and baseline. 4. subjects who are suitable for continue using biological treatment assessed by investigator exclusion criteria: 1. acute onset of ad within 4 weeks before drug administration. 2. the accompany disease have been assessed by the investigators during screening period as unsuitable for participation in this study. 3. any history or symptoms of malignant tumors in any organ within 5 years prior to screening, regardless of whether treatment has been received and whether there are signs of recurrence or metastasis 4. have a known or suspected history of immunosuppressive diseases, including a history of invasive infections. 5. having undergone or planned major surgery within 4 weeks prior to drug administration, or unable to fully recover from surgery prior to drug administration. 6. any medical or psychological condition that puts subjects at risk or may affect the study results assessed by investigators.
a dosing and efficacy study of intra-nasal sufentanil for moderate to severe pain

Conditions: Pain; Opiate

Summary: the purpose of this study is to determine the appropriate dose and effectiveness of intra-nasal administration of a potent narcotic, sufentanil, for the treatment of moderate to severe pain due to broken bone(s) in the arm or leg.


Eligibility criteria:
inclusion criteria: * 18 years old or older; * isolated traumatic injury to upper or lower extremity; * alert and oriented to name, date, place; patient has a numeric pain score of 5 or higher; * speaks english as their primary language; * female patients are on birth control, menopausal, or are sterile (hysterectomy, tubal ligation) exclusion criteria: * injury isolated to a finger or toe; * previous nasal or sinus surgery; chronic nasal problem; * acute nasal problem (ie epistaxis, upper respiratory infection, sinusitis); * pregnant; prisoner; allergy to sufentanil, fentanyl, or alfentanil; history of analgesic abuse or dependency; * presence of other painful injuries; systolic blood pressure less than 100 mm hg; * patient seems or is confused or has a head injury; room air oxygenation less than 95%; * patient has chronic obstructive pulmonary disease, severe asthma, oxygen-dependent pulmonary disease; * impaired hepatic or renal function (obtained clinically or by history); * weight more than 230 lbs (100 kg); * alcohol or drug intoxication (per patient admission or clinical assessment of physician); * elderly (\> 70 years)

Keywords: acute pain, intranasal, sufentanil, acute pain control with an intranasal opiate
bronchoscopic intratumoral chemotherapy for small cell lung cancer (sclc)

Conditions: Small Cell Lung Cancer

Summary: this project proposes to use bronchoscopic intratumoral chemotherapy for small cell lung cancer in two fashions: 1. to implement a prospective clinical trial to test the feasibility and efficacy of intralesional chemotherapy as consolidative therapy immediately following standard systemic chemotherapy and radiation therapy for patients with limited stage sclc by comparing tumor growth and survival rates of the treatment group and compare the outcomes to historical controls 2. to implement a prospective clinical trial to test the feasibility and efficacy as measured by tumor growth and survival rates of intralesional chemotherapy for patients with recurrent sclc after standard treatment.

subjects will receive standard of care treatment for sclc with added treatment of cisplatin injection via endobronchial ultrasound aided bronchoscopy a total of four times. outcome measurements of tumor growth and survival will be compared to subjects receiving standard of care treatment only.

Eligibility criteria:
inclusion criteria: competent adult english speaking subjects * with limited stage sclc who have completed standard of care treatment who are responders with no evidence of disseminated disease other than cns metastasis, * with recurrent disseminated sclc after standard of care treatment with symptoms related to central tumor obstruction, * with recurrent limited stage sclc with mediastinal/hilar recurrence not previously treated with intratumoral cisplatin exclusion criteria: * subjects who do not meet the inclusion criteria * subjects who, in the opinion of the investigator, are at risk undergoing a bronchoscopy
impact of reinforced education by video on the quality of bowel preparation

Conditions: Bowel Preparation Scale; Adenoma Detection Rate

Summary: high quality bowel preparation is essential for successful colonoscopy. this study aimed to assess the impact of reinforced education by video on the quality of bowel preparation. this prospective, endoscopist-blinded, randomized, controlled study was conducted. reinforced education groups received additional education via reminders by video 2 days before colonoscopy. the primary outcome was the quality of the bowel preparation according to the boston bowel preparation scale (bbps). the secondary outcomes included polyp detection rate (pdr), adenoma detection rate (adr), tolerance, and subjective feelings of patients.


Eligibility criteria:
inclusion criteria: * outpatients aged 18-80 years * referred for routine diagnostic colonoscopy * with access to the educational video themselves or through close family members living in the same household were eligible. exclusion criteria: 1. pregnancy or breastfeeding 2. allergy to purgatives 3. suspected intestinal obstruction, stricture, or perforation 4. hemodynamic instability 5. impaired swallowing reflex or mental status 6. severely medical status, such as new york heart association grade iii or grade iv congestive heart failure and severe renal failure 7. illiteracy 8. history of oesophagus、stomach 、duodenum、small intestine or colorectal surgery 9. participation declined.

Keywords: polyp detection rate adenoma detection rate boston bowel preparation scale
a randomized controlled trial of routine shave margins versus standard partial mastectomy in breast cancer patients

Conditions: Breast Cancer

Summary: this research study is designed to look at whether the routine use of shave margins (by taking extra tissue at the time of partial mastectomy surgery) will reduce the chances of having positive surgical margins requiring another surgical procedure, and whether this affects the long-term chances of getting cancer back in your breast.


Eligibility criteria:
inclusion criteria: 1. breast cancer, stage 0-3, deemed a surgically appropriate candidate for partial mastectomy with planned procedure for the same. 2. women ≥ 18 years of age. 3. ability to understand and the willingness to sign a written informed consent document. exclusion criteria: 1. patients who have received previous neoadjuvant chemotherapy 2. patients who require a total mastectomy 3. known metastatic breast cancer.
effect of artronat on the quality of life of patient with osteoarthritis

Conditions: Osteoarthritis

Summary: the purpose of this study is to determine whether the nutritional supplement artronat improves the quality of life of patients with osteoarthritis.

osteoarthritis is a degenerative disease that greatly impairs the quality of life of patients. a nutritional supplement may help, in association with the normal treatment of osteoarthritis, improving the quality of life of such patients, in reducing pain and/or improving join flexibility.

Eligibility criteria:
inclusion criteria: * age 40-75 years * bmi 18.5-30 * osteoarthritis type ii or iii exclusion criteria: * osteoarthritis type i or iv * allergy to one of the component of the supplement * blood pressure \> 14/8 * history of knee surgery

Keywords: gonalgia quality of life dietary supplement nutrition